+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 73 Actively Recruiting clinical trials

A

Actively Recruiting

Malignant hypertension is a very serious form of high blood pressure that can be fatal if untreated. This research aims to create the first large, multicenter database to better understand this disease, including its modern epidemiology, how patients are currently managed, and the diseases diagnostic criteria. The study will help improve knowledge and may lead to new treatment trials and evidence-based recommendations. The study is an observational registry enrolling patients diagnosed with malignant hypertension based on classic definitions, including severe blood pressure elevation and organ damage. It plans to recruit 500 patients and follow them for five years to study their prognosis and the impact of different patient characteristics and organ involvement. By collecting detailed data on disease features and care pathways, the study hopes to update definitions and management approaches. Participants will be observed over five years, with researchers collecting information on their health status, organ damage, and treatment. The main outcome measured is the five-year prognosis of patients. This long-term follow-up will provide detailed knowledge about the disease course and help identify factors influencing outcomes, without any study treatments or interventions being assigned.

Age: 18Years +All Genders
37 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
O

Actively Recruiting

Researchers are studying the effects of anifrolumab, given as a 120 mg subcutaneous injection once weekly, for patients with systemic lupus erythematosus SLE who have not used immunosuppressants or biologic therapies before. The study aims to understand clinical outcomes like remission rates and the ability to taper off glucocorticoids GCs safely in patients not meeting low disease activity status at enrollment. Participants will receive anifrolumab injections weekly for 52 weeks, alongside their usual antimalarial treatment, with or without glucocorticoids. The study includes a 35-day screening period before treatment starts. Glucocorticoid doses may be increased during the first 4 weeks if needed, then tapered gradually between weeks 5 and 40 following a specific protocol. Those achieving remission can attempt complete withdrawal of glucocorticoids after tapering. After week 41, glucocorticoid doses will remain stable. Safety follow-up occurs 12 weeks after the last dose for participants who stop treatment after week 52. Participants will undergo regular assessments throughout the study to evaluate disease activity, remission status, glucocorticoid use, and quality of life. Researchers will monitor various outcomes, including time spent in remission, flare occurrences, skin and joint symptoms, and adverse events. The total participation time is approximately 69 weeks, including screening, treatment, and safety follow-up, with detailed tracking of glucocorticoid use and disease status at multiple time points.

Age: 18Years - 70YearsAll GendersPhase 3
107 locations
A

Actively Recruiting

This research aims to improve treatment and survival quality for infants, children, and young adults aged 0 to 45 years with acute lymphoblastic leukaemia ALL. It combines experiences from multiple European study groups into a master protocol that offers comprehensive risk stratification and treatment plans. The study includes randomized and interventional trials to identify therapies that may be less toxic and more effective, particularly focusing on reducing relapse and treatment-related side effects. Participants receive treatment based on a master protocol considered standard care, with additional randomized interventions testing modifications like reducing or omitting specific chemotherapy drugs such as Doxorubicin, Vincristine, and Dexamethasone. Some patients receive experimental treatments including Inotuzumab ozogamicin, Imatinib, 6-tioguanine, and Blinatumomab. Specific sub-studies also examine pharmacokinetics, neurocognitive outcomes, and cerebrospinal fluid diagnostics. The study design allows modular addition or stopping of sub-protocols and interventions. Throughout the study, participants undergo various assessments including monitoring of disease progression, side effects, and drug activity. Researchers evaluate event-free survival, disease-free survival, minimal residual disease response, and overall survival over multiple years, with follow-up periods extending up to 8 years. Participants cognitive functions and treatment toxicities are also assessed using specialized tests and questionnaires. Safety and adverse events are closely monitored to better understand treatment impacts over time.

Age: 0Years - 45YearsAll GendersPhase 3
137 locations
G

Actively Recruiting

Researchers are conducting an international clinical program to improve diagnosis, treatment, and understanding of childhood ependymoma in patients under 22 years old. The study aims to harmonize staging and care standards, assess biological markers, and develop treatment recommendations based on age, tumor location, and surgical outcomes. Patients are categorized into three groups based on residual disease and eligibility for radiotherapy to test different therapeutic strategies. The study includes three treatment strata Stratum 1 evaluates the impact of a 16-week chemotherapy regimen with VEC-CDDP after surgery and conformal radiotherapy in patients aged over 12 months to under 22 years with completely removed tumors. Stratum 2 examines the addition of high-dose methotrexate to VEC chemotherapy in patients with residual disease, followed by conformal radiotherapy and possibly an 8 Gy radiotherapy boost for inoperable residual tumors. Stratum 3 studies dose-dense chemotherapy with or without valproate in children under 12 months or those ineligible for radiotherapy. Patients not meeting these criteria enter an observational registry. Participants undergo centralized pathology and imaging reviews to confirm diagnosis and tumor resection status. Assessments include MRI scans, biological marker evaluations, and response to treatments. Researchers monitor progression-free survival, gross total resection rates, treatment response, neuropsychological and neuroendocrine effects, and safety over several years. The study involves scheduled visits, laboratory tests, and follow-up for up to five years to evaluate long-term outcomes.

Age: 0 - 22YearsAll GendersPhase 2Phase 3
40 locations
S

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with ALK gene rearrangement treated with next-generation tyrosine kinase inhibitors TKIs as first-line therapy. This prospective study, part of the national EXPLORE ALK cohort, aims to understand the biological characteristics and resistance mechanisms of this cancer type. It involves patients with stage IIIB or IV NSCLC who are not eligible for curative locoregional treatment and have confirmed ALK rearrangement. The study collects tumor tissue samples at diagnosis and at disease progression, if available, to analyze ALK fusion partners, variants, and co-mutations using RNA sequencing. Blood samples are taken at diagnosis, first tumor evaluation, and disease progression to analyze circulating tumor DNA ctDNA with next-generation sequencing. Treatments studied include alectinib, brigatinib, lorlatinib, and entrectinib, either marketed or under early access programs. Participants provide blood samples and allow use of tumor tissue for centralized biological analyses. Researchers measure progression-free survival up to 72 months as the primary outcome, along with overall survival, response rates, duration of response, ctDNA clearance, and resistance mechanisms associated with treatment and ALK fusion partners. The study involves regular evaluations over several years to monitor treatment outcomes and biological changes.

Age: 18Years +All GendersPhase Not Applicable
46 locations
C

Actively Recruiting

Researchers are evaluating the best anesthetic approach for patients with severe ischemic stroke undergoing mechanical thrombectomy MT, a procedure to open blocked brain vessels. This trial compares general anesthesia GA, which requires breathing support and induces unarousable sleep, with procedural sedation PS, which uses a lighter sedation without respiratory assistance. The study aims to determine which method better improves functional independence three months after stroke, addressing conflicting results from previous smaller trials. Participants will receive either GA, involving intubation and controlled ventilation with specific anesthetic drugs and strict blood pressure management, or PS, involving lighter sedation with spontaneous breathing and targeted sedation medications. Both groups will be monitored closely during the procedure and postoperatively, with vital signs, blood pressure, blood sugar, and oxygen levels carefully controlled. After the intervention, patients are transferred to stroke care units for further monitoring including brain imaging within 24 to 48 hours. Throughout their hospital stay and after discharge, participants will be assessed for functional outcomes using the modified Rankin Scale at 90 days, along with other measures such as cognitive function, quality of life, and stroke severity scales. Researchers will evaluate procedural success, complications, and recovery progress. Follow-up includes telephone interviews at three months to determine independence in daily life and overall recovery, with the study concluding around three years after enrollment begins.

Age: 18Years +All GendersPhase Not Applicable
16 locations
C

Actively Recruiting

Researchers are evaluating different antibiotic treatments for patients in intensive care units who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. The study compares the effects of using one antibiotic monotherapy versus a combination of two antibiotics, as well as shorter 7 days versus longer 14 days treatment durations. This research also looks at how resistant the bacteria are to antibiotics and how often pneumonia recurs in these patients. The study involves observing patients who meet specific criteria without assigning new treatments directly. It focuses on the antibiotic strategies already being used, comparing their impact on patient survival. The main measurement is survival within 28 days based on the treatment strategy applied. There are no additional experimental interventions since this is an observational study. Participants will be adult patients who were hospitalized in a medical intensive care unit between January 1, 2018, and December 31, 2023, who were intubated and mechanically ventilated with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia. The research team collects data on patient outcomes, antibiotic resistance, and pneumonia recurrence. The study aims to understand which antibiotic approaches may support better survival in this group.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Philadelphia-negative myeloproliferative neoplasms MPNs such as Polycythemia Vera, Essential Thrombocythemia, and Prefibrotic Myelofibrosis are chronic blood cancers caused by mutations affecting blood cell growth. These diseases carry a high risk of blood clots, which can cause serious complications and death. Current treatments include low-dose aspirin, but blood clots still occur in some patients despite therapy. This trial aims to study whether direct oral anticoagulants DOACs, which have shown benefits in other cancer patients, might help prevent blood clots in MPN patients with a specific mutation called JAK2V617F. Participants will be randomly assigned to receive either a direct oral anticoagulanteither Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once dailyor low-dose aspirin 100 mg once daily. The choice of DOAC is up to the investigator. The treatments will be given to high-risk patients for up to 24 months to compare their effects on clot prevention. Throughout the study, participants will be closely monitored for any thrombotic or bleeding events. During the trial, researchers will track the time until any arterial or venous blood clots occur, as well as any major or clinically relevant bleeding events. They will also evaluate survival, adherence to therapy, quality of life, and healthcare costs related to these treatments. Participants will have regular follow-ups over 24 months, including assessments for heart rhythm problems and safety monitoring. This comprehensive approach aims to better understand the benefits and risks of DOACs compared to aspirin in preventing clots in MPN patients.

Age: 18Years +All GendersPhase 3
42 locations
C

Actively Recruiting

Researchers are conducting the BIOMEDE 2.0 study, a phase 3 clinical trial to evaluate and compare the effectiveness of ONC201 versus everolimus in treating patients with Diffuse Intrinsic Pontine Glioma DIPG and related diffuse midline gliomas. This multicenter randomized trial aims to determine if ONC201 is superior to everolimus in improving progression-free survival. Patients with these brain tumors will be enrolled, and the study may also compare results to historical controls. Participants will be randomly assigned to receive either everolimus tablets once daily or ONC201 capsules twice weekly according to specified dosing schedules. All patients will also undergo radiotherapy as part of standard care. Treatment continues until unacceptable toxicity, confirmed tumor progression, or withdrawal of consent. After disease progression, patients may switch to the other treatment arm following a 7-day washout period or receive reirradiation if applicable. Throughout the study, participants will undergo regular clinical and radiological evaluations to monitor tumor status and side effects. The primary outcome measured is progression-free survival up to two years after the last patient is included. Secondary outcomes include overall survival, safety profiles, and complication rates related to diagnostic biopsies, with long-term follow-up extending up to five years. Patients will be closely monitored for treatment tolerability and disease progression during the trial period.

Age: 6Months +All GendersPhase 3
56 locations

1-10 of 73

1